Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 30%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group is a promising company with strong potential in the medical technology industry. The company's Organ Care System (OCS) technology has the potential to transform the organ transplantation process by replicating near-physiologic conditions for donor organs. However, there are several risks that could impact the company's future prospects, including limited market commercialization experience, regulatory challenges, and customer concentration. Despite these risks, the company's solid financial performance and potential for further growth make it an attractive investment opportunity.

Bears say

TransMedics Group is facing increased expenses and projected decrease in earnings per share, with potential external factors such as OPO modernization and competition from XVIVO's HOPE technology. Surgeons have mixed opinions on TMDX becoming an OPO, but the company remains a growth company with potential for success. Decreasing costs in the market may also impact the company's competitiveness and surgeons may consider cheaper alternatives for organ preservation methods. While the company has acquired new R&D, it is important to closely monitor its financials and market developments.

TMDX has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 30% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 10 analysts, TMDX has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.